Sander joined TGS Baltic in 2013 and became a partner in 2018. Co-heading the M&A practice, he is involved in most of the firm’s transactional work, while his special focus is on pharmaceuticals and IT.
His recent M&A work highlights include advising Euroapteek, part of the Nordic and Central and Eastern Europe’s leading pharmacy group Euroapotheca, on the acquisition of Ülikooli Apteek pharmacy chain in Estonia and advising pharmaceuticals producer Kevelt, a subsidiary of MSE listed company, in selling its IP rights to oncologic drug candidate Virexxa to a listed US biopharmaceuticals company Xenetic Biosciences in the first and only transaction of its kind in Estonia.
Sander has a long track-record of experience in the pharmaceuticals industry, including advertising and clinical trials. His clients include international pharmaceutical companies Merck Sharp & Dohme and Oribalt whom he advises on daily basis in various legal fields including promotion and marketing of medicinal products, corporate/commercial, M&A, data protection and other regulatory matters.
Sander is a member of the Ministry of Justice’s corporate law audit committee that has been set up to review all legislation regulating the corporate/commercial field. Also, he co-authored the suretyship and guarantee sections’ commentaries on the General Part of the Law of Obligations Act
He teaches contract law, company law and M&A at the University of Tartu, the main legal education provider in Estonia.
Sander is fluent in Estonian, English and German